Medical Device JCAs Launch and NICE Methodology Shifts

MarcusWelcome to Access Brief, the daily AI podcast on HEOR, HTA, and market access. I'm Marcus, with Sara. Today: medical device JCAs starting June, NICE's updated tranexamic acid guidance, and the natalizumab biosimilar decision logic. Let's get into it.

SaraThe EU JCA medical device rollout begins this month with approximately 5 assessments for high-risk devices. Class IIb, III, and Class D in vitro diagnostics are entering formal JCA process according to the HTACG Annual Work Programme.

MarcusThis is the real test case for JCA methodology beyond pharmaceuticals. Medical devices present fundamentally different evidence challenges – shorter clinical trial programs, iterative development cycles, learning curve effects that don't exist in drug assessment.

SaraExactly. And with only 5 assessments launching, they're clearly being cautious about capacity. The question is whether the methodology framework developed for pharmaceuticals can handle the evidence heterogeneity we see in device dossiers.

MarcusThe learning curve issue alone could break their current approach. Device performance improves with surgical experience in ways that pharmaceutical efficacy simply doesn't. You can't model that with traditional clinical endpoints.

SaraPlus the commercial implications are immediate. Unlike drugs where you might have 12-18 month HTA timelines, device companies need faster market access to generate the real-world evidence that actually matters for long-term adoption.

MarcusNICE updated their tranexamic acid guidelines on May 13, removing the requirement for clinicians to estimate blood loss during surgery. They're calling it procedural simplification, focusing just on bleeding risk rather than quantified loss estimates.

SaraThis looks like NICE trying to improve implementation compliance by reducing administrative burden. But I'm skeptical about whether removing the blood loss estimation actually maintains the same evidence standard.

MarcusThe clinical effectiveness doesn't change based on administrative complexity. If anything, the blood loss estimation requirement was creating artificial precision where none existed. Most surgical blood loss estimates are notoriously inaccurate anyway.

SaraBut that's exactly my point. If the blood loss estimates were unreliable, then the original evidence base that supported the recommendation might have been built on weak implementation assumptions. Simplifying the guidance doesn't fix the underlying evidence gap.

MarcusYou're conflating research evidence with clinical implementation guidance. The RCT evidence for TXA effectiveness is robust regardless of how individual clinicians estimate blood loss in practice. NICE is just acknowledging implementation reality.

SaraI disagree. When you change the implementation criteria, you're potentially changing the patient population that receives treatment. That has direct implications for real-world effectiveness and cost-effectiveness that weren't captured in the original economic model.

MarcusThe natalizumab decision demonstrates NICE's increasingly sophisticated biosimilar assessment approach. They recommended subcutaneous Tysabri and Tyruko biosimilar infusion for highly active relapsing-remitting MS, but explicitly excluded intravenous Tysabri on cost-effectiveness grounds.

SaraThis is smart positioning for pregnancy planning patients since natalizumab can be used during pregnancy unlike other highly effective DMTs. But the formulation-specific cost-effectiveness analysis shows how complex biosimilar value assessment is becoming.

MarcusWhat's interesting is the differentiation within the same molecule based purely on delivery mechanism and cost structure. They're essentially saying the clinical benefit is equivalent but the economic value proposition differs by formulation.

SaraIt also signals to manufacturers that biosimilar strategies need formulation-specific economic modeling, not just bioequivalence demonstrations. The commercial implications extend beyond simple price competition to value-based differentiation.

MarcusThe EMA welcomed the Critical Medicines Act political agreement on May 12, highlighting improved availability and production of critical medicines across the EU. Their Executive Steering Group will conduct supply chain vulnerability assessments to inform policy measures.

SaraThis connects directly to HTA methodology because supply chain resilience becomes part of the value equation. When you're assessing critical medicines, availability risk should factor into health technology assessment frameworks.

MarcusThe supply chain vulnerability assessments could generate valuable real-world data on medicine shortages and alternative therapy utilization patterns. That data becomes input for future HTA economic modeling.

SaraBut it also creates regulatory complexity. If EMA identifies supply chain vulnerabilities for specific medicines, HTA bodies might need to adjust their cost-effectiveness thresholds or recommendation frameworks to account for availability risk.

MarcusMedical devices hit JCA methodology this month. NICE continues refining implementation guidance while developing more sophisticated value differentiation approaches.

SaraThe question is whether these procedural simplifications actually strengthen evidence standards or just make weak implementation more palatable. We'll see how device JCAs handle the methodology gaps.

MarcusBack tomorrow on Access Brief. Show notes at outcomes-analytica.no.